GlassScriptPhysician profile
Lawrence R Mccormack
NPI 1831168608
$11,987.73
in general payments reported to CMS, 2019-2025
36 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,324 · 2020: $1,630 · 2021: $1,757 · 2022: $2,139 · 2023: $2,571 · 2024: $567.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,104 · Education: $33.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,103.91 |
| Education | $33.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,644.76 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,744.96 | 2019-2023 | Trulance, Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $1,694.53 | 2019-2024 | Entyvio, Gattex |
| Janssen Biotech, INC. | $873.79 | 2019-2023 | Stelara, Simponi Aria, Simponi |
| Pfizer INC. | $656.25 | 2019-2024 | |
| Gilead Sciences, INC. | $540.48 | 2019-2024 | Epclusa |
| Intercept Pharmaceuticals, INC. | $485.55 | 2019-2024 | Ocaliva |
| Celgene Corporation | $219.13 | 2021-2024 | Zeposia |
| Genzyme Corporation | $193.00 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $168.27 | 2019-2024 | Dificid |
| Ferring Pharmaceuticals INC. | $147.54 | 2019-2023 | Rebyota |
| Qol Medical, LLC | $142.12 | 2022-2024 | Sucraid, Sucraid |
| Nestle Healthcare Nutrition INC. | $141.30 | 2021-2023 | |
| Daiichi Sankyo INC. | $137.32 | 2019-2023 | Injectafer |
| Ucb, INC. | $134.31 | 2019-2020 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $120.40 | 2022-2024 | Dupixent |
| Braintree Laboratories, INC. | $112.19 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $105.67 | 2023-2024 | Cyltezo |
| Janssen Scientific Affairs, LLC | $100.59 | 2019 | |
| Aimmune Therapeutics, INC. | $93.84 | 2023-2024 | |
| Vivus LLC | $77.76 | 2021-2024 | Qsymia |
| Concordia Pharmaceuticals INC. | $69.20 | 2019 | |
| Shionogi INC | $58.11 | 2019-2020 | |
| Alfasigma USA, INC. | $42.84 | 2020-2021 | |
| Mallinckrodt Hospital Products INC. | $37.05 | 2023-2024 | Terlivaz |
| Amag Pharmaceuticals, INC. | $35.10 | 2019-2021 | |
| Olympus America INC. | $32.15 | 2021-2022 | |
| Amgen INC. | $25.11 | 2023 | Avsola, Amjevita |
| Allergan, INC. | $22.73 | 2019 | |
| Alnylam Pharmaceuticals INC. | $22.22 | 2022 | |
| Sandoz INC. | $21.60 | 2023 | Hyrimoz |
| Exact Sciences Corporation | $21.00 | 2023 | Cologuard Collection Kit |
| Albireo Pharma, INC. | $20.69 | 2022 | |
| Endogastric Solutions, INC | $18.22 | 2023 | Esophyx |
| Phathom Pharmaceuticals, INC. | $14.62 | 2024 | Voquezna |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $13.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Mccormack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.